about   CII home   shop   checkout

Venture Capitalist Panel

Ted DriscollTed Driscoll, Ph.D., Technology Partner, Claremont Creek Ventures

Ted Driscoll is a Technology Partner at Claremont Creek Ventures. He is also an active angel investor in the Life Science Angels, Health Tech Capital and a founding director of the Sand Hill Angels.

Prior to his venture capital experience, Ted helped found five successful companies in imaging-related markets. He was founder and CEO of Be Here Technologies, a pioneer in Internet, Broadcast and Videoconferencing technologies. He served as a Division President and CTO of Diasonics, with responsibility for its MRI, ultrasound, digital X-ray, lithotripsy and acoustic ablation technology areas. He had earlier directed the Diasonics technology team that developed the first commercial MRI scanners and numerous advances in MR imaging. Previously, Ted was also Vice President of Engineering and R&D of Identix, now a world leader in fingerprint and face recognition; and Director of R&D at International Imaging Systems, an early pioneer in remote sensing. His research and patents in ultrasound therapy and acoustic hemostasis also led to the founding of another company, Therus, now partnered with Boston Scientific.

Ted holds a Ph.D. from Stanford University in Digital Imaging, Masters degrees from Harvard University in Computer Graphics and Remote Sensing and a Bachelor’s degree from the University of Pennsylvania. Ted holds 40+ granted US and foreign patents in imagerelated fields, with approximately 30 additional pending applications.

Rowan Chapman Rowan Chapman, Partner, Life Science, Mohr Davidow Ventures

A Partner at Mohr Davidow, Rowan Chapman was the first dedicated member of the life science investment team. She joined the firm in 2001 and has been central to developing the life science thesis that led directly to many of the firm’s life science investments. Her particular interest lies in the translation of complex data and technology to innovative products that impact drug and biofuel discovery, personalized medicine and healthcare decision making.

Leveraging her 19 years of business and technical experience as well as industry relationships, she works closely with entrepreneurs to help develop successful businesses. Rowan is a board member of Sequenta and VitaPath Genetics, as well as a board observer at Artemis Health, Pacific Biosciences, Adamas Pharmaceuticals, CardioDx and Tethys Bioscience.

Prior to joining Mohr Davidow, Rowan was an early employee at Rosetta Inpharmatics where she held the position of Director of Business Development until its acquisition by Merck for $620M. Previously, Rowan held the position of marketing manager at Incyte Genomics. Rowan holds a Ph.D. in cellular and molecular biology from Cambridge University and was a postdoctoral fellow at UCSF.

David Hanzel David Hanzel, Ph.D., Partner, X/Seed Capital

David Hanzel is a Partner at X/Seed Capital who is trained as a physiologist and protein biophysicist and has held both scientific and business positions at a number of start-ups and large corporations. His specialties include imaging technologies, molecular biology, protein production and synthetic and surface chemistry. Before joining X/Seed Capital, David was Vice President for Product Marketing and Reagent Development at Pacific Biosciences. Prior to that he was Principal Scientist at Molecular Dynamics and stayed with that company through its acquisition by General Electric. Among his roles at GE Healthcare, David was a Principal Scientist and the Scientific Lead for cell-based high throughput screening systems. David was a Co-Founder and Director of Intellectual Property and Collaborations at Aeomica, a spinout of Amersham, focused on human gene discovery. He has authored more than 20 peer-reviewed papers and is co-inventor in 15 patents. David holds a Ph.D. and a BA from the University of California at Berkeley. He did post-doctoral work at Cornell University Medical College.


Gino Di Sciullo Gino Di Sciullo, Ph.D., Partner, Charter Life Sciences

Gino is a Partner at Charter Life Sciences, a healthcare focused venture capital fund headquartered in Silicon Valley. CLS invests in early stage companies developing new medical devices, pharmaceutical products, diagnostics and healthcare services.

Gino is involved in all aspects of due diligence leading to new investments and he supports and manages companies in the CLS portfolio. He joined the fund in 2006 and has been involved with investments in APT Pharmaceuticals, Amaranth Medical, Mirabilis Medica and Great Lakes Pharmaceuticals. He earned his degree in Pathology from Boston University School of Medicine in 1998.

Download Conference & Course Catalog

CHI Catalog Cover